The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|April 1, 2005
Upcoming Conference, to be held April 8th, 2005, Provides Compelling New Thoughts on Pharmaceutical and Medical Device Marketing
Agency.com, Alliance Healthcare Information, BBDO, Hall & Partners Healthcare, and Targetbase are sponsoring an upcoming conference, Can Pharmaceutical and Medical Device Marketers Learn From the Automobile Industry? Yes...here's why.
Advertisement
Upcoming Conference, to be held April 8th, 2005, Provides Compelling New Thoughts on Pharmaceutical and Medical Device Marketing
Agency.com, Alliance Healthcare Information, BBDO, Hall & Partners Healthcare, and Targetbase are sponsoring an upcoming conference, Can Pharmaceutical and Medical Device Marketers Learn From the Automobile Industry? Yes...here's why. The conference will be held on Friday, April 8, 2005, at the Hyatt Regency Princeton, Princeton, New Jersey.
The conference will introduce many new and incisive thoughts regarding how Pharmaceutical and Medical Device companies can learn from other industries' best practices as they relate to DTC, more targeted communications, and compliance. Topics covered will include:
- The purchase process, as identified and defined by the automobile industry through extensive research, and an explanation of its resemblance to the pharmaceutical and medical device purchase process.
- Building awareness and interest via pharmaceutical DTC advertising and how DTC's role parallels that of automotive national advertising.
- How the healthcare industry can leverage proven direct and database marketing strategies that are being successfully deployed in the automobile industry today.
- What common threads exist when building brands in the pharmaceutical and automotive spheres.
Upcoming/Add one
- The comparable roles of cyberspace in the two equations.
- How considered purchase service programs are similar to pharmaceutical compliance/adherence programs.
An expert lineup of speakers will feature Lewis G. Pringle, PhD, former EVP and Research Director of BBDO Worldwide and holder of the Chair of Marketing at Miami of Ohio University, currently Chairman of the Department of Managerial Economics and Professor of Marketing at Yorktown University; Thomas Abrams, R.Ph., MBA, Director, Branch Chief Marketing & Surveillance Branch 1 with DDMAC of the FDA; as well as other industry experts in the pharmaceutical and automobile markets.
The conference is free, by INVITATION ONLY, and will include breakfast and lunch. If you are interested in this conference and would like to be added to the invitation mailing list, please e-mail Sarah Schaeffer,
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5